Letter to Dreesen et al. on their article 'Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease'-A comprehensive review of infliximab population pharmacokinetic modelling publications

Le Tilly Olivier; Bejan-Angoulvant Theodora; Paintaud Gilles; Ternant David

首页> 外文期刊>British Journal of Clinical Pharmacology >Letter to Dreesen et al. on their article 'Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease'-A comprehensive review of infliximab population pharmacokinetic modelling publications

【24h】

Letter to Dreesen et al. on their article 'Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease'-A comprehensive review of infliximab population pharmacokinetic modelling publications

机译：德莱森等人。关于他们的文章“毛细血管暴露，粪便抗癌素，患者患者内镜缓解患者的关系的建模” - 富胎巴比人群药代动力学造型出版物的全面综述

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《British Journal of Clinical Pharmacology》 |2021年第3期|共2页
作者
Le Tilly Olivier; Bejan-Angoulvant Theodora; Paintaud Gilles; Ternant David;
展开▼
作者单位

Univ Tours Tours France;

Univ Tours Tours France;

Univ Tours Tours France;

Univ Tours Tours France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献

1. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease [J] . Dreesen Erwin, Berends Sophie, Laharie David, British Journal of Clinical Pharmacology . 2021,第1期

机译：克罗恩病患者粪便抑制，粪便冲击，粪便冲击素和内镜缓解关系的建模
2. De-escalation of Infliximab Maintenance Therapy from 8-to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease [J] . Papamichael Konstantinos, Karatzas Pantelis, Mantzaris Gerasimos J. Journal of Crohn’s & colitis . 2016,第3期

机译：基于粪便钙卫蛋白的克罗恩病患者，英夫利昔单抗维持治疗从8到10周给药间隔的降级
3. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study [J] . D. Laharie, S. Mesli, F. El Hajbi, Alimentary Pharmacology & Therapeutics . 2011,第4期

机译：英夫利昔单抗治疗者中粪便钙卫蛋白对克罗恩病复发的预测：一项前瞻性研究
4. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn’s Disease [O] . Konstantinos Papamichael, Pantelis Karatzas, Gerasimos J. Mantzaris -1

机译：克罗恩病患者基于粪便钙卫蛋白的英夫利昔单抗维持治疗从8到10周的给药间隔逐步降低
5. Letter to Dreesen et al. on their article “Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease”—A comprehensive review of infliximab population pharmacokinetic modelling publications [O] . Olivier Le Tilly, Theodora Bejan‐Angoulvant, Gilles Paintaud, 2020

机译：德莱森等人的信。关于他们的文章“毛细血管曝光，粪便抗突素，患有克罗恩病患者内镜缓解的关系的建模” - 富胎动力学建模出版物的全面综述

Letter to Dreesen et al. on their article 'Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease'-A comprehensive review of infliximab population pharmacokinetic modelling publications

著录项

相似文献

相关主题

期刊订阅